About this trial
Researchers are looking for new ways to treat people with endometrial cancer (EC) who have previously received treatment with platinum based therapy (a type of chemotherapy) and immunotherapy. Immunotherapy is a treatment that helps the immune system fight cancer. This clinical study will compare MK-2870 sacituzumab tirumotecan to chemotherapy. The goal of the study is to learn if people who receive MK-2870 (sacituzumab tirumotecan) live longer overall and without the cancer getting worse compared to people who receive chemotherapy.
Patient Profile
In participants at least 18 years of age with endometrial cancer who have previously received both systemic, platinum-based chemotherapy and anti-PD-1/anti-PD-L1 therapy, either
separately or in combination.
Where’s this trial being run?
Cork University Hospital, St James’s Hospital, and Mater Misericordiae University Hospital
Can I join this study / trial?
The first step we recommend is to talk to your doctor or the cancer trials team at your hospital. You can find contact details for cancer trials research units in Ireland here.
It’s also a good idea to print this page and bring it with you to your appointment. It can help guide the conversation and remind you of what to ask. You may also want to talk to your family or friends about your options, as they can offer support as you make decisions.
For more detailed information
Click HereQuestions?
Here’s a list of questions you may have for your doctor or local cancer research team.
QuestionsSummary Data
| Name: | ENGOT-en23 / PREVENTER |
|---|---|
| Number: | 23-04 |
| Full Title: | A Phase 3, Randomized, Active-controlled, Open-label, Multicentre Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician’s Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Immunotherapy (MK-2870-005/ENGOT-en23/GOG-3095). |
| Principal Investigator: | Dr. Dearbhaile Collins |
|---|---|
| Type: | Collaborative |
| Sponsor: | MSD |
| Recruitment Started: |
Global: December 2023 Ireland: June 2024 |
| Global Recruitment Target: | 710 |
|---|---|
| Ireland Recruitment Target: | 15 |